NURTEC ODT (rimegepant orally disintegrating tablets) is indicated for:
Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
Geriatrics (≥ 65 years of age): Clinical trials with rimegepant did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects.
)NURTEC ODT (rimegepant orally disintegrating tablets) is indicated for:
Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
Geriatrics (≥ 65 years of age): Clinical trials with rimegepant did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects.
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.